85 results
8-K
TXMD
TherapeuticsMD Inc
10 Jul 23
Changes in Registrant's Certifying Accountant
5:20pm
years ended December 31, 2022 and December 31, 2021 and the subsequent period to the date of its engagement, neither the Company nor anyone acting
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
Days after its engagement). The Firm shall make its determination only with respect to the matters still in dispute and, with respect to each
8-K
l7a1hyd igrpq9ob
25 Jul 22
Entry into a Material Definitive Agreement
8:00am
SC 14D9/A
mftjc zg2w4
28 Jun 22
Tender offer solicitation (amended)
4:31pm
SC 14D9
rdtjl4
10 Jun 22
Tender offer solicitation
6:51pm
SC TO-T
EX-99
w9jfh5rl
6 Jun 22
Third party tender offer statement
5:02pm
8-K
EX-2.1
3mlw5j6
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
8-K
EX-99.1
5aw ypshaj
4 Aug 21
TherapeuticsMD Announces Second Quarter 2021 Financial Results
7:00am
8-K
EX-99.2
rd918yq z3
4 Aug 21
TherapeuticsMD Announces Second Quarter 2021 Financial Results
7:00am
8-K
EX-1.1
ws1q mv8bm
16 Feb 21
Entry into a Material Definitive Agreement
8:35am
8-K
EX-99.1
ycew4wyo72mxb5
13 Jan 21
Entry into a Material Definitive Agreement
8:50am
8-K
EX-1.1
p9nvw2i7omns8zagm
13 Nov 20
Entry into a Material Definitive Agreement
12:00am